Articles By Jack Cush, MD
RheumNow Week in Review – 9 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com.
Read Article
CanVasc Recommendations for ANCA-Associated Vasculitis
ANCA associated vasculitis (AAV) has undergone considerable study and advances in the last few years.
Read Article
Physicians Still Over-Prescribe Antibiotics, Narcotics and Opioids
A study by the American College of Physicians (ACP) found that physicians continue to prescribe treatments that offer little benefit to patients, despite the advice of clinical guidelines.
Read Article
Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study
The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.
Read Article
Is ABT-494 the Next JAK Inhibitor?
Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.
Read Article
The RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read Article
CURES Act : House Passes Largest Bill Since Obamacare
The 21st Century Cures Act has become one of the most-lobbied health care bills in recent history, with nearly a half billion dollars being spent on both sides - those for and against the bill.
Read Article
ASDAS Activity Correlates with Xray Progression in Spondyloarthritis
Investigators analyzed a prospective study of patients with early axial spondyloarthritis (axSpA) to assess predictors of outcome.
Read Article
Rheumatologist Compensation and Manpower
You should use this information to not only fend for yourself, but to more accurately guide trainees into a richly rewarding specialty that pays well and has many distinctions to boast of, including high science, hands-on patient interactions and long-term relationships, great hours, lifestyle and family friendly careers. Our field is in desperate need of high quality, problem-solving practitioners.
Read Article
Ustekinumab Effective and Safe in Crohn's Colitis
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Read Article